Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer (vol 71, pg 297, 2024)

被引：0

作者：

Ying, Xixi ^{[1
,2
]}

Shi, Zheng ^{[3
,4
]}

Shao, Rongjun ^{[1
,2
]}

You, Guangxian ^{[2
]}

Song, Zhengbo ^{[1
,3
,4
]}

机构：

[1] Zhejiang Chinese Med Univ, Grad Sch, Hangzhou, Zhejiang, Peoples R China

[2] Taizhou Canc Hosp, Dept Radiol & Oncol, Taizhou, Peoples R China

[3] Wenzhou Med Univ, Zhejiang Canc Hosp, Postgrad Training Base Alliance, Hangzhou, Zhejiang, Peoples R China

[4] Zhejiang Canc Hosp, Dept Clin Trial, Hangzhou, Zhejiang, Peoples R China

来源：

关键词：

D O I：

10.4149/neo_2024_231104N572COR

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1